Alnylam Pharmaceuticals (ALNY) Faces Investor Fraud Probe
Alnylam Pharmaceuticals (NASDAQ: ALNY) is under investigation for alleged securities law violations. The probe follows a significant stock drop after the company lowered its 2026 sales guidance on July 30, 2026, citing market dynamics. Schall, Brown & Schwartz LLP is leading the investigation into whether Alnylam issued misleading statements or failed to disclose pertinent information to investors.